Published on:
March 23, 2026
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal diagnosis and treatment. If you or someone else develops symptoms that may indicate bacterial meningitis or meningococcal septicaemia, call 999 immediately — this is a medical emergency.
Meningitis B has rarely generated as much public concern in the UK as it has in the spring of 2026. An outbreak centred on Canterbury — with cases subsequently linked to London — has resulted in deaths, dozens of hospitalisations, and a national scramble for vaccines. If you are a parent, a student, or simply someone trying to understand your risk, this guide covers everything you need to know: what MenB is, how it spreads, what the symptoms look like, who is eligible for a vaccine, and why stocks have run dry across the country.
Meningitis is an inflammation of the membranes surrounding the brain and spinal cord. Several different bacteria and viruses can cause it, but the bacterium Neisseria meningitidis type B — commonly called MenB — is one of the most prevalent strains in the United Kingdom. According to the charity Meningitis Now, MenB is among the most common causes of bacterial meningitis in the country, and it can progress from early symptoms to life-threatening illness within hours.
The bacteria spreads through close, prolonged contact with an infected person — sharing saliva via kissing, drinking from the same bottle, or spending extended time in crowded indoor spaces. It does not spread through casual contact such as breathing the same air briefly or touching surfaces. Most people who carry the bacteria in their throat never become ill themselves, but they can transmit it to others who may be more vulnerable.
MenB can also cause meningococcal septicaemia — a serious bloodstream infection — which is frequently more dangerous than meningitis alone. The combination of the two conditions is what makes the disease so potentially fatal, particularly in young children and adolescents whose immune systems may not respond quickly enough.
Early symptoms of MenB closely resemble those of flu — fever, headache, muscle aches, and fatigue — which makes it easy to dismiss in the first few hours. As the infection progresses, more distinctive signs may appear. These can include a stiff neck, sensitivity to bright light, severe headache, vomiting, and a high temperature that does not respond to paracetamol or ibuprofen.
The rash associated with meningococcal septicaemia is one of the most widely recognised warning signs. It begins as small red or purple spots that do not fade when you press a glass against them — the so-called "tumbler test". The spots can quickly spread into larger blotches. Pale, blotchy, or mottled skin, cold hands and feet, and confusion or difficulty staying awake are also signs that medical help is urgently needed.
If you or someone you know develops these symptoms — particularly the non-blanching rash — call 999 immediately. Do not wait to see whether the rash spreads. Bacterial meningitis can become fatal within 24 hours of onset, and early treatment with intravenous antibiotics significantly improves outcomes. Our page on viral infections outlines how viral and bacterial illnesses differ, which can help you understand early symptoms in context — but this should never delay seeking emergency care if meningitis is suspected.
The NHS introduced the MenB vaccine (brand name Bexsero) into the routine childhood immunisation schedule in September 2015. Babies receive their first dose at eight weeks, a second at sixteen weeks, and a booster at one year. This programme has been highly effective for the age group it covers, reducing MenB cases in infants significantly since its introduction.
However, teenagers and young adults — the age group most affected in the current outbreak — are not routinely offered the MenB vaccine on the NHS. The Joint Committee on Vaccination and Immunisation (JCVI) has assessed that vaccinating adolescents is not cost-effective at a population level, partly because the absolute risk of MenB in any individual teenager remains low. Health Secretary Wes Streeting has asked the government's vaccination advisory body to review this position in light of the outbreak, but no change to national policy has been announced at the time of writing.
This policy gap is exactly why the current outbreak has caused such alarm. Many of the students affected in Canterbury were born before 2015 and therefore received no MenB vaccination at any point. They are, in effect, an unprotected generation. The vaccine is available privately for older children and adults, but at a cost that not all families can readily absorb — and stocks have now become extremely difficult to obtain.
The outbreak emerged in Canterbury in early March 2026, initially linked to students at the University of Kent. Two young people died, and by mid-March the total case count had risen to 27, with authorities describing it as the largest cluster of cases in a generation. A number of students were hospitalised, and at least one case was identified in a person who had visited Canterbury but subsequently fell ill in London. A further case was linked to France.
The UK Health Security Agency (UKHSA) confirmed the strain as MenB and launched a major public health response. Approximately 30,000 doses of preventative antibiotics were administered to close contacts, including people who had attended Club Chemistry, a nightclub in Canterbury, between 5 and 15 March. UKHSA regional deputy director Trish Mannes confirmed that around 2,500 doses of antibiotics had been given across sites in Kent alone, with contact tracing teams working to reach anyone who may have been exposed.
As a further precaution, NHS England began rolling out a targeted MenB vaccination programme for students living on the Canterbury campus and those who had visited the nightclub during the relevant period. Up to 5,000 University of Kent students were offered the vaccine. Officials stated they believed the outbreak was being contained, with no confirmed cases appearing outside the original cluster at the time of that assessment.
The speed and scale of the response reflects how seriously public health authorities treated the situation. Meningococcal outbreaks in university settings can be difficult to contain because of the close-contact nature of student life — shared accommodation, social venues, and communal facilities all create conditions that favour transmission. Our travel clinic team advises students and travellers on vaccination schedules relevant to their circumstances, including meningococcal vaccines where appropriate.
Within days of the outbreak becoming public, pharmacies across the country reported little to no stock of Bexsero, the MenB vaccine. The UKHSA's Chief Scientific Officer, Professor Robin May, was compelled to address the shortage publicly after reports of pharmacies being overwhelmed with requests. The shortage was not caused by a manufacturing failure — it was driven by a sudden and extraordinary surge in demand from parents and young people seeking private vaccinations.
Health Secretary Wes Streeting explicitly urged people not to seek private vaccinations, emphasising that the risk of transmission outside the immediate cluster was low and that the primary public health intervention — antibiotics for close contacts — was working. Despite this, public anxiety drove a nationwide rush that quickly outstripped available supply. Bexsero is produced by pharmaceutical company GSK, and supply chains for specialist vaccines are not designed to absorb rapid spikes in demand of this magnitude.
The shortage has highlighted a broader structural issue: the UK holds limited strategic reserves of vaccines that are not part of the routine NHS schedule. When an outbreak occurs and private demand spikes simultaneously, supply cannot keep pace. UKHSA and NHS England have prioritised existing stocks for those directly linked to the outbreak, meaning the vaccine is being directed to the highest-risk individuals in Canterbury rather than distributed across private clinics nationally.
If you are concerned about your own vaccination history or that of your child, speaking to a GP is the most reliable starting point. A private GP can assess your individual risk, review your vaccination records, and advise you on what is currently available. Routine vaccinations such as the flu vaccine remain unaffected by the current shortage.
There is no home treatment for confirmed bacterial meningitis. Anyone presenting with symptoms consistent with MenB must be assessed in a hospital setting immediately — call 999 or go to your nearest A&E without delay. Treatment involves high-dose intravenous antibiotics — typically benzylpenicillin (administered by GPs or paramedics as a pre-hospital dose if MenB is strongly suspected) or ceftriaxone in hospital — given as early as possible. Early administration is critical, as even a short delay can affect outcomes.
For people who have been in close contact with a confirmed case but are not yet symptomatic, doctors may prescribe preventative antibiotics — most commonly ciprofloxacin, or rifampicin as an alternative — to reduce the chance of infection taking hold. This is the intervention that public health authorities have prioritised during the Kent outbreak, and it is why 30,000 doses of antibiotics were distributed so rapidly.
Recovery from MenB can be lengthy. Survivors may face complications including hearing loss, memory problems, scarring, and in severe cases, limb amputation as a result of tissue damage caused by septicaemia. Early treatment significantly reduces the likelihood of these outcomes, which is why the rash and other severe symptoms must never be waited out at home. If you have general health concerns — whether for yourself or your child — and wish to discuss them with a clinician in a non-emergency context, our same-day GP consultation service is available. Please note that any symptoms suggestive of meningitis or septicaemia always require immediate emergency care via 999 or A&E rather than a GP appointment.
For parents of children born before September 2015, or for young adults who did not receive the vaccine in infancy, private vaccination may be a reasonable option when supply allows. The vaccine requires two doses given at least one month apart for primary immunisation in teenagers and adults (the interval may differ for younger children — your GP will advise on the appropriate schedule), so it is not an instant solution in the context of an active outbreak.
If you live in or around Canterbury, or you know that someone in your household has been identified as a close contact of a confirmed case, you should follow UKHSA guidance and access the NHS response pathway rather than attempting to source a private vaccine independently. For everyone else, the risk of contracting MenB outside the current cluster remains low, and seeking a private vaccine should not take priority over the supply needed for those directly affected.
That said, many families with older children who missed the routine infant schedule choose to vaccinate privately as a precautionary measure. Once supply stabilises, this is a conversation worth having with your GP — particularly if your child is approaching the age when they will be living in close-contact settings such as university halls of residence.
Meningitis can be caused by several different bacteria and viruses. The most common bacterial strains in the UK are types B and C. MenC has been largely controlled through a well-established NHS vaccination programme, which is why MenB now accounts for the majority of bacterial meningitis cases. Viral meningitis, while often less severe, can also cause significant illness. MenB specifically refers to infection with Neisseria meningitidis serogroup B bacteria.
The NHS routine schedule covers babies because they are at the highest statistical risk of severe MenB disease. The JCVI reviewed evidence on vaccinating adolescents and concluded that the cost per case prevented did not meet the threshold required for a national programme. Critics argue this assessment does not adequately weigh the severity of outcomes in young people, and the Kent outbreak has prompted renewed political pressure on this decision.
Current evidence suggests that protection from Bexsero is strongest in the years immediately following vaccination, but the long-term duration of immunity is still being studied. Children vaccinated in infancy may have reduced antibody levels by the time they reach adolescence, which is one reason some clinicians recommend a booster dose for teenagers who were vaccinated as babies, particularly before they move into higher-risk environments such as university accommodation.
Yes. Bexsero is licensed for use in individuals from two months of age with no upper age limit. Adults who have not previously been vaccinated can receive a two-dose course from a private GP or travel clinic when stock is available. Adults with certain medical conditions that affect immunity may be eligible for the vaccine on the NHS — your GP can advise based on your individual circumstances.
Call 999 or go to your nearest A&E immediately. Do not wait for a GP appointment. If someone develops a non-blanching rash, severe headache, stiff neck, fever, pale or mottled skin, or becomes difficult to rouse, this is a medical emergency. Every hour matters. Early intravenous antibiotics are the single most important factor in improving survival and reducing long-term complications.
The information provided in this article is for educational purposes only and is based on NHS recommendations. It is not a substitute for professional medical advice. Always consult your doctor or a qualified healthcare provider for advice on medical conditions or treatments.
Our medical centre is at 36 Spital Square, E1 6DY, City of London.
